DLTs in phase I trials of Aurora kinase inhibitors were primarily hematological events, particularly neutropenia [15–18], and DLTs for CSF-1R inhibitor included INR increase, lymphopenia, AST increase, anemia, neutropenia, and syncope [10]. The gene discussed is CSF1R; the disease is anemia (phenotype).